Moderna, Inc. Finance Lease, Liability, Current
Moderna, Inc. (MRNA) had Finance Lease, Liability, Current of $31.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:FinanceLeaseLiabilityCurrent · last filed 2026-07-31
- 2026-06-30: Finance Lease, Liability, Current $31.00M.
- 2026-03-31: Finance Lease, Liability, Current $31.00M.
- 2025-12-31: Finance Lease, Liability, Current $25.00M.
- 2025-09-30: Finance Lease, Liability, Current $31.00M.
| Period end | Finance Lease, Liability, Current | Finance Lease, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $31.00M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $31.00M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $25.00M 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $31.00M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $27.00M 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $28.00M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $23.00M 10-K · filed 2026-02-20 | |
| 2024-09-30 | $30.00M 10-Q · filed 2024-11-07 | |
| 2023-12-31 | $0.00 10-K · filed 2025-02-21 | |
| 2023-09-30 | $150.00M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $187.00M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $153.00M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $161.00M 10-K · filed 2024-02-23 | |
| 2022-09-30 | $224.00M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $121.00M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $160.00M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $165.00M 10-K · filed 2023-02-24 | |
| 2021-09-30 | $218.00M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $159.00M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $45.00M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $24.00M 10-K · filed 2022-02-25 | $24.33M 10-K · filed 2021-02-26 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |